



## Bryce Cooper

Partner

Chicago

+1 312-558-3737

Recognized as a “Rising Star” and “tenacious litigator,” Bryce is a trial lawyer who concentrates his practice on mass torts, products liability, and pharmaceutical patent litigation while doing extensive pro bono work and community service.

Bryce is a partner in the firm’s litigation department, concentrating his practice on mass torts, products liability, complex commercial, and pharmaceutical patent litigation, with a primary focus in the health care and agribusiness industries. Recognized on *Benchmark Litigation’s* “40 & Under Hot List,” by the National LGBT Bar as one of its “Best LGBTQ+ Lawyers Under 40,” and as one of Law360’s Product Liability “Rising Stars,” Bryce has litigated high-profile and high-stakes cases through trial on a range of consumer products, including Roundup®, preterm infant formula, PFAS, and numerous nutritional products and medical devices. Bryce has also been extensively involved in successful representations of generic pharmaceutical companies against claims of patent infringement and has taken many of them to trial. He has represented numerous clients through trial and appeal, including Bayer AG, Monsanto Company, Abbott Laboratories, Boeing Company, Archer-Daniels-Midland, Teva Pharmaceuticals, Sun Pharmaceuticals, and MSN Pharmaceuticals. Most recently, Bryce was recognized in the 2024 edition of *IAM Patent 1000* and as a “Key Lawyer” in *The Legal 500 US* (2021–2024).

# Key Matters

Bryce has significant experience in all aspects of litigation in federal and state courts from discovery through trial and appeal. Notable representations include:

- Currently representing global health care company in mass torts litigation alleging that cow milk-based infant formula products cause a naturally occurring gastrointestinal disorder in premature infants.
- Currently representing a chemical manufacturer against environmental and products liability claims alleging groundwater contamination and personal injury.
- Obtained a jury trial victory in favor of a medical device manufacturer in products liability action alleging design defect, manufacturing defect, failure to warn, and negligence claims related to a breakthrough cardiac artery stenting product.
- Obtained two trial victories for generic pharmaceutical company establishing noninfringement of patents that blocked generic competition for Cabometyx® (cabozantinib), a cancer treatment drug. The trial victory may allow generic versions of the drug to launch years before the patents-in-suit would have expired.
- Obtained a trial victory for generic pharmaceutical companies invalidating four patents that blocked generic competition for the drug Ampyra® (dalfampridine), which improves walking in patients with multiple sclerosis. The trial victory and affirmance at the Federal Circuit allows generic versions of the drug to launch almost a full decade before the patents-in-suit would have expired.
- Represented Monsanto Company in the first Roundup® product liability and failure-to-warn case to go to trial in the country. Following an eight-week jury trial, the trial team successfully reduced a punitive damages award by US\$211 million, and the verdict was further reduced on appeal. Obtained dismissal of another Roundup® suit before trial.
- Obtained a jury trial victory for a global ingredients and ethanol producer in an action for fraudulent inducement against an equipment provider that claimed to have developed a proprietary and revolutionary technology for use in the production of ethanol. After a three-week trial, a New York County jury rejected the equipment manufacturer's US\$180 million damages claim and instead awarded our client rescission of the license agreement and the return of its licensing payments.
- Defeated a bellwether case claiming that food ingredient manufacturers were liable for plaintiff's overconsumption of sweetened foods and resulting health that *Forbes* described as "the most notorious illustration of how a baseless lawsuit can effectively demonize one disfavored food ingredient."
- Represented an airplane manufacturer in a series of products liability actions alleging toxic air exposure.
- Represented a medical device manufacturer in numerous products liability actions alleging design defect, manufacturing defect, failure to warn, and negligence claims related to cardiac guide wire products.
- Represented manufacturers of high fructose corn syrup in a high-profile false advertising matter brought by members of the sugar industry. The suit challenged the freedom of the corn refiners to educate the public about high fructose corn syrup.
- Represented dental trade associations in their defense of antitrust and business tort claims brought by a competing trade association, obtaining victory on a motion to dismiss.
- Represented Seven Seas Partnership Limited, a film financing company, in its breach of contract suit brought against Terrence Malick's production company for failure to timely complete the feature film, *Voyage of Time*.

Bryce's representation of generic pharmaceutical companies against claims of patent infringement span a variety of drug products including Lidoderm®, Entocort®, Metadate CD®, Remodulin®, Ampyra®, Istodax®, Tyvaso®, Orenitram®, Lincress®, Myrbetriq®, Hetlioz®, Invokana®, Invokamet XR®, Jardiance®, Glyxambi®, Synjardy XR®, Cabometyx®, Briviact®, and Ocaliva®.

# Recent Experience

Winston Serves as Trial Counsel in Monsanto Roundup Litigation

## Recognitions

- Recognized in *IAM Patent 1000* (2024)
- Named in Law360 as a Product Liability “Rising Star” (2022)
- Recognized by *Best Lawyers: Ones to Watch® in America* in the areas of Commercial Litigation and Litigation-Intellectual Property (2022–2023)
- Listed by *Crain’s Chicago Business* as a “Notable Rising Star in Law” (2021)
- Recognized by *The Legal 500 US* as a “Key Lawyer” in the areas of Dispute Resolution: Product Liability, Mass Tort and Class Action - Defense: Pharmaceuticals and Medical Devices (2021–2024); Dispute Resolution: Product Liability, Mass Tort and Class Action - Defense: Toxic Tort (2023–2024) and Dispute Resolution: Product Liability, Mass Tort and Class Action - Defense: Consumer Products (including Tobacco) (2023–2024)
- Named to *Benchmark Litigation US’s* “40 & Under List” (2020–2023) and recognized as a “Future Star” (2025)
- Recognized by The National LGBT Bar as one of its “Best LGBTQ+ Lawyers Under 40” (2020)
- Recognized by *Crain’s Chicago Business* as one of its “Notable LGBTQ Executives” (2019)
- Recognized by *Chicago Magazine* as a “Rising Star” (2014–2018)
- Winston & Strawn was named by *The National Law Journal* as the “Chicago Litigation Department of the Year” for general litigation (2015)

---

## Activities

Bryce previously served as President of the Board of Directors for the Legal Council for Health Justice and previously served on the Board for Cabrini Green Legal Aid. Bryce is also a leading member of Winston’s PRIDE group. Additionally, Bryce is a member of DRI.

Bryce’s extensive pro bono work includes the re-trial and acquittal of one defendant who had wrongfully served 15 years in prison for double homicide, and a summary judgment victory for inmates who had brought an action against the Prisoner Review Board, Department of Corrections, and Cook County State’s Attorney’s Office for violations of the Prisoner Review Board statutes and regulations and Freedom of Information Act.

He served as co-counsel in *M.A. v. Norwood* in the Northern District of Illinois, which successfully challenged the Illinois Department of Healthcare and Family Service’s unconstitutional reductions of in-home nursing services to Medicaid-eligible children. He also served as co-counsel in *Deese, et al. v. Mattis, et al.* and *Wilkins, et al. v. Austin* in the District of Maryland, which successfully challenged and overturned the Department of Defense’s unconstitutional policies excluding service members living with HIV.

---

“ [Bryce] leverages his technical understanding and comprehensive grasp of patent law to position himself as the preferred partner for pharmaceutical clientele. ”

# Credentials

## EDUCATION

Bryce received a J.D. from the University of Chicago Law School in 2008 and a B.A. in Political Science from the University of Notre Dame in 2005.

## ADMISSIONS

- Illinois

## Related Insights & News

“Decoding Novel Cases: Key Insights from Groundbreaking Rulings in *Gilead*, *BMS*, *Bartlett*, and More,” American Conference Institute Drug & Medical Device Litigation, Panelist, Dec. 3, 2024

“The Realities of Mass Torts: In-House Perspectives,” Winston & Strawn Product & Mass Torts Summit, Speaker, June 7, 2022

---

## BLOG

Supreme Court Has a Chance to (Re-)Clarify *Albrecht* Impossibility Preemption Test

APRIL 3, 2025

---

## BLOG

A Natural Solution: Court Dumps Microplastic Suit for Lack of Scientific Evidence

MARCH 27, 2025

---

## SPONSORSHIP

Winston Sponsors, Bryce Cooper and Matt Saxon Speak at ACI Drug & Medical Device Conference

DECEMBER 3, 2024

---

## BLOG

Proximate Cause with Teeth: Recent Case-Dispositive Expert Exclusions in Product Liability Cases

NOVEMBER 21, 2024

---

## RECOGNITIONS

Winston & Strawn Recognized in 2025 *Benchmark Litigation*

OCTOBER 3, 2024

---

## PRO BONO IN ACTION

Winston Wins Third Landmark Victory Against the DOD Allowing People Living with HIV to Serve Their Country

**BLOG**

Winston Hosts Annual 1L LCLD Scholars Roundtable  
JUNE 17, 2024

---

**RECOGNITIONS**

Winston & Strawn Recognized in *The Legal 500 U.S.* 2024  
JUNE 12, 2024

---

**RECOGNITIONS**

Winston Recognized in 2024 *IAM Patent 1000* Rankings  
JUNE 5, 2024

---

**PRO BONO IN ACTION**

Winston Caps Historic Victory for Military Service Members with HIV by Celebrating Commissioning of Lead Plaintiff Nick Harrison  
NOVEMBER 10, 2023

---

**RECOGNITIONS**

Winston & Strawn Recognized in 2024 *Benchmark Litigation*  
OCTOBER 6, 2023

---

**RECOGNITIONS**

Winston Partners Named to *Benchmark Litigation's* 2023 40 & Under List  
JULY 31, 2023

---

Capabilities

---

Commercial Litigation & Disputes

Intellectual Property

Litigation/Trials

Patent Litigation

Product Liability & Mass Torts

Food & Beverage

Media & Entertainment

Medical Devices